Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
6Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
NewAmsterdam Pharma Company N.V. (NAMS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
2Distinct source URLs
6High confidence
0.776Average confidence
2026-07-05Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
NewAmsterdam Pharma Company N.V. Suppliers
Ticker
Name
Confidence
Evidence
A-MENARINI-INTERNATIONAL-LICENSING-S-A
A-MENARINI-INTERNATIONAL-LICENSING-S-A
92%
NewAmsterdam Pharma B.V. entered into a supply agreement with A. Menarini International Licensing S.A. ("Menarini") to provide commercial supply of Products (as defined below) for distribution in spe…
NewAmsterdam Pharma Company N.V. Customers
Ticker
Name
Confidence
Evidence
MENARINI
MENARINI
92%
In addition, Menarini is expected to purchase obicetrapib and obicetrapib and ezetimibe FDC tablets from us in accordance with a supply agreement to be entered into by Menarini and us
FRAZIER-LIFE-SCIENCES-ACQUISITION-CORPORATION
FRAZIER-LIFE-SCIENCES-ACQUISITION-CORPORATION
62%
ntities under common control. NewAmsterdam Pharma Holding B.V. and Frazier Life Sciences Acquisition Corporation had no material operations, and the mergers had no impact on the consolidated financia…
GR8-PEOPLE-INC
GR8-PEOPLE-INC
62%
ntly impacts our ability to generate revenue. At the end of each reporting period, we assess the probability of significant reversals for any amounts that become likely to be realized prior to recogn…
MITSUBISHI-TANABE-PHARMA-CORPORATION
MITSUBISHI-TANABE-PHARMA-CORPORATION
62%
-how of the patented drug Obicetrapib and the in-process research and development (“IPR&D”). The Company paid consideration of € 1 for the IPR&D asset and could potentially make an additional conting…
RENAISSANCE-AVENTURA-LLC
RENAISSANCE-AVENTURA-LLC
62%
ntly impacts our ability to generate revenue. At the end of each reporting period, we assess the probability of significant reversals for any amounts that become likely to be realized prior to recogn…
USA-LLC
USA-LLC
62%
, control of the product is transferred upon the conveyance of title, which occurs when the product is made available to the customer. The transaction price is contractually fixed at a markup to the …
NewAmsterdam Pharma Company N.V. Debt Obligations
Instrument
Description
Confidence
Evidence
NAMS-DEBT
Debt stack $202,000
90%
Market cache reports total debt of $202,000.
NAMS-DEBT-11162
Warrants outstanding: 1638000
90%
xbrl warrant detail from xbrl 2025-12-31.
NAMS-DEBT-11163
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
NewAmsterdam Pharma Company N.V. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for NewAmsterdam Pharma Company N.V..
NewAmsterdam Pharma Company N.V. Ownership
Holder
Name
Confidence
Evidence
NAMS-OWNER-FRAZIER-LIFE-SCIENCES-MANAGEMENT
Frazier Life Sciences Management, L.P.
90%
13F overlay lists Frazier Life Sciences Management, L.P. as top holder; 173 tracked holders.
NewAmsterdam Pharma Company N.V. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
NewAmsterdam Pharma Company N.V. Supply Chain Intel
